• Home
  • Store
    • Total Access Subscriptions
    • Newsletter Subscriptions
    • Multimedia
    • Books
    • eBooks
    • ABPN SA Courses
    • Institutional Site Licenses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
    • Psychotherapy and Social Work
  • Toolkit
  • FAQs
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Access Purchased Content
Home » Dextromethorphan as Early Augmentation for Mild to Moderate Depression
Research Update

Dextromethorphan as Early Augmentation for Mild to Moderate Depression

August 1, 2026
Rida Fatima, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Rida Fatima, MD.

Dr. Fatima has no financial relationships with companies related to this material.


PDF


Getting your Trinity Audio player ready...

REVIEW OF: Maji S et al, Psychiatry Res 2024;342:116257

STUDY TYPE: Randomized, double-blind, placebo-controlled clinical trial

Dextromethorphan is best known as an over-the-counter cough suppressant, but it also acts as an NMDA receptor antagonist (like ketamine) and modulates serotonin and norepinephrine. It’s already paired with bupropion in the combo pill Auvelity, where bupropion’s CYP2D6 inhibition prolongs the action of 90 mg of dextromethorphan. This study investigated lower doses of dextromethorphan with SSRIs for early augmentation in mild to moderate MDD.

Researchers randomly assigned 60 adults—about half under 35—to receive either 30 mg/day of dextromethorphan or a placebo for 8 weeks. All had been depressed for about 6–7 weeks and had started SSRIs (the equivalent of 50 mg of sertraline) within 4 weeks. Patients with a history of substance use were excluded. The primary outcome was change in Montgomery–Åsberg Depression Rating Scale (MADRS) score. Secondary measures included response (≥ 50% improvement), remission (MADRS < 7), Clinical Global Impression Scale (CGI) scores, and tolerability.

Patients receiving dextromethorphan showed a significantly greater MADRS reduction, with a large effect size (Cohen’s d = 1.05) and nearly double the response and remission rates of patients receiving placebo. CGI improvements were also significantly better. The treatment was well tolerated, with no serious adverse events. Improvement was most pronounced in those with moderate depression and in patients receiving sertraline; however, the effects of paroxetine and fluoxetine were hard to study given the low sample size.

CARLAT TAKE
If you want to add dextromethorphan to an antidepressant, bupropion is currently the only FDA-approved option. However, this single-center study investigating recent episodes of depression in a relatively young population also supports the use of 30 mg of SSRIs. Paroxetine and fluoxetine inhibit CYP2D6, but sertraline doesn’t, so it’s unfortunate that this trial didn’t have the power to detect differences between individual SSRIs. If you try this off label, the simplest and cheapest approach is OTC immediate-release dextromethorphan, rather than combination cough products.
General Psychiatry
KEYWORDS dextromethorphan
    Rida Fatima, MD

    More from this author
    www.thecarlatreport.com
    Issue Date: August 1, 2026
    SUBSCRIBE NOW
    Table Of Contents
    Learning Objectives, Insight, TCPR, August 2026
    Pharmacological Treatments for Autism
    When Patients Don’t Know They Are Ill
    Mirtazapine Helps Older Adults Sleep, but Side Effects Limit Staying Power
    Dextromethorphan as Early Augmentation for Mild to Moderate Depression
    Exercise Doesn’t Always Work
    Sedation Trajectories With Antipsychotics: Practical Insights From a Meta-Analysis
    CME Post-Test, Insight, TCPR, August 2026
    DOWNLOAD NOW
    Featured Book
    • MFB8e_SpiralCover.png

      Medication Fact Book for Psychiatric Practice, Eighth Edition (2026)

      Updated 2026 prescriber's guide.
      READ MORE
    Featured Video
    • KarXT (Cobenfy)_ The Breakthrough Antipsychotic That Could Change Everything.jpg
      General Psychiatry

      KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

      Read More
    Featured Podcast
    • shutterstock_2818113403.jpg
      General Psychiatry

      Adult ADHD 1: The Child Grows Up

      Listen now
    Recommended
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png
    • Join Our Writing Team

      July 18, 2024
      WriteForUs.png
    • Insights About a Rare Transmissible Form of Alzheimer's Disease

      February 9, 2024
      shutterstock_2417738561_PeopleImages.com_Yuri A.png
    • How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

      May 24, 2024
      DEA_Checkbox.png

    About

    • About Us
    • CME Center
    • FAQ
    • Contact Us

    Shop Online

    • Newsletters
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN Self-Assessment Courses

    Newsletters

    • The Carlat Psychiatry Report
    • The Carlat Child Psychiatry Report
    • The Carlat Addiction Treatment Report
    • The Carlat Hospital Psychiatry Report
    • The Carlat Geriatric Psychiatry Report
    • The Carlat Psychotherapy Report

    Contact

    carlat@thecarlatreport.com

    866-348-9279

    PO Box 626, Newburyport MA 01950

    Follow Us

    Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

    © 2026 Carlat Publishing, LLC and Affiliates, All Rights Reserved.